Abstract 1492P
Background
Due to the widespread uptake of 6-weekly Pembrolizumab (6wklyP) in the COVID-19 era, this audit attempts to clarify differences in clinically relevant immune therapy related adverse events (irAEs) between 6wklyP and traditional 3-weekly Pembrolizumab (3wklyP).
Methods
Oncology patients at the Gold Coast University Hospital with Advanced Melanoma or Metastatic Non-small cell lung cancer (NSCLC) who received single agent 3wklyP 200mg, 6wklyP 400mg or those who sequentially received 3wklyP followed by 6wklyP between 2017-2022 were analysed for frequency of clinically significant (Grade3-4) irAEs. Total time of immunosuppression for treatment of irAEs was recorded. Data was extracted from the electronic medical record and analysed using Cox-proportion hazard analysis.
Results
In total, 69 and 112 patients received 6wklyP and 3wklyP respectively. There were 52 patients with Melanoma and 129 patients with NSCLC. 30 patients received sequential treatment. Average observation time for toxicity was 327 days for 6wklyP and 352 days for 3wklyP. 17/69 (24.6%) patients who received 6wklyP developed Grade 3-4 irAEs compared with 9/112 (8%) 3wklyP patients (HR of 3.03; CI 1.34-6.83, p= 0.007). Grade 1-4 irAEs were 32/69 (46.4%) with 6wklyP and 31/112 (27.7%) with 3wklyP. 6/30 (20%) patients who received 6wklyP after initially receiving 3wklyP had Grade 3-4 irAEs (HR 0.56, CI 0.24-1.37; p= 0.187). Mean immunosuppression time for treatment of Grade 3-4 irAEs for 6wklyP and 3wklyP was 91 days and 55 days respectively (p =0.76). 6/17 (35.3%) 6wklyP patients required Steroid sparing agents to treat their Grade3-4 irAEs compared to 1/9 (11.1%) 3wklyP patients.
Conclusions
6wklyP was associated with significantly higher immune therapy related adverse events than 3wklyP. Sequential delivery of 6wklyP after 3wklyP did not significantly alter clinically significant adverse effects. Immunosuppressive management of irAEs were not statistically different between arms however there was a higher rate of steroid sparing immunomodulation requirement with 6wklyP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21